Open AccessHyperkalemia in heart failure
Author(s) -
Kiran Sidhu,
Rohan Sanjanwala,
Shelley Zieroth
Publication year - 2020
Publication title -
current opinion in cardiology/current opinion in cardiology, with evaluated medline
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.826
H-Index - 78
eISSN - 1080-787X
pISSN - 0268-4705
DOI - 10.1097/hco.0000000000000709
Subject(s) - hyperkalemia , medicine , heart failure , intensive care medicine , kidney disease , hemodialysis , population , environmental health
Hyperkalemia is increasingly prevalent in the heart failure population as more people live with heart failure and comorbid conditions such as diabetes and chronic kidney disease. Furthermore, renin-angiotensin-aldosterone (RAAS) inhibitors are a key component of clinical therapy in these populations. Until now, we have not had any reliable or tolerable therapies for treatment of hyperkalemia resulting in inability to implement or achieve target doses of RAAS inhibition. This review will focus on two new therapies for hyperkalemia: patiromer and sodium zirconium cyclosilicate (SZC).